Reconciling Mystical Experiences with Naturalistic Psychedelic Science: Reply to Sanders and Zijlmans.
ACS Pharmacol Transl Sci June 8, 2021
Reconciling Mystical Experiences with Naturalistic Psychedelic Science: Reply to Sanders and Zijlmans.
ISSN 2575-9108
4 papers in the library · 842 citations · publishing 2020-2021
ACS Pharmacol Transl Sci June 8, 2021
Reconciling Mystical Experiences with Naturalistic Psychedelic Science: Reply to Sanders and Zijlmans.
ACS Pharmacol Transl Sci March 16, 2021 Jake Payne, Richard Chambers, Paul Liknaitzky 80 citations
Psychedelic and mindfulness interventions have been shown to improve mental ill-health and wellbeing, with a range of clinical processes and effects in common. However, each appear to contain specific challenges in the context of mental health treatment. In this Perspective, we focus on a set of distinct affordances, "useful differences", within psychedelic and mindfulness interventions that...
ACS Pharmacol Transl Sci March 5, 2021 Jacob S. Aday, Alan K. Davis, Cayla M. Mitzkovitz et al. 228 citations
Psychedelic drugs are increasingly being incorporated into therapeutic contexts for the purposes of promoting mental health. However, they can also induce adverse reactions in some individuals, and it is difficult to predict before treatment who is likely to experience positive or adverse acute effects. Although consideration of setting and dosage as well as excluding individuals with psychotic...
ACS Pharmacol Transl Sci December 10, 2020 David B. Yaden, Roland R. Griffiths 534 citations
Classic psychedelics produce altered states of consciousness that individuals often interpret as meaningful experiences. Across a number of human studies, when the participant-rated intensity of the overall drug effects are statistically controlled for, certain subjective effects predict therapeutic and other desirable outcomes. Underlying neurobiological mechanisms are likely necessary but not...